Startup Funding Tracker
Home›People›Joshua Makower
JM

Joshua Makower

Director at X9. Also a director at Moximed, Intrinsic Therapeutics and Willow Innovations.

DirectorPublic companyRoles at 4 startups
Updated Nov 9, 2026·Latest SEC filing Dec 5, 2025·Suggest an edit

About Joshua Makower

Joshua Makower is a director at X9.

Form D filings also name Joshua Makower as a director at Moximed, Intrinsic Therapeutics and Willow Innovations.

Joshua Makower reports to the SEC as a director or major shareholder of 27 public companies, including Eargo (EAR), Berkshire Grey (BGRY) and Robinhood Markets (HOOD).

Joshua Makower first appears on SEC filings in 2009.

Experience

This experience comes from SEC filings. The years are when the filings name Joshua Makower in the role, so the role may have started earlier or lasted longer.

X9, Inc.
Director
2022 – 2025 · Wallingford, CT
Moximed, Inc
Director
2009 – 2024 · Fremont, CA
Eargo, Inc.
Director and 10% owner
2020 – 2022 · Public company (EAR)
Berkshire Grey, Inc.
10% owner
2021 · Public company (BGRY)
Robinhood Markets, Inc.
Director and 10% owner
2021 · Public company (HOOD)
NeueHealth, Inc.
10% owner
2021 · Public company (NEUE)
Monte Rosa Therapeutics, Inc.
10% owner
2021 · Public company (GLUE)
Desktop Metal, Inc.
10% owner
2020 – 2021 · Public company (DM)
OnKure Therapeutics, Inc.
10% owner
2021 · Public company (OKUR)
Intrinsic Therapeutics Inc.
Director
2010 – 2021 · Woburn, MA
Marker Therapeutics, Inc.
10% owner
2018 – 2021 · Public company (MRKR)
Savara Inc
10% owner
2021 · Public company (SVRA)
Regulus Therapeutics Inc.
10% owner
2017 – 2021 · Public company (RGLS)
Verona Pharma plc
10% owner
2021 · Public company (VRNA)
Willow Innovations, Inc.
Director
2015 – 2020 · Mountain View, CA
Metacrine, Inc.
10% owner
2020 · Public company (MTCR)
Inozyme Pharma, Inc.
10% owner
2020 · Public company (INZY)
Genocea Biosciences, Inc.
10% owner
2018 – 2020 · Public company (GNCA)
Annexon, Inc.
10% owner
2020 · Public company (ANNX)
Nkarta, Inc.
10% owner
2020 · Public company (NKTX)
Akouos, Inc.
10% owner
2020 · Public company (AKUS)
Aveo Pharmaceuticals, Inc.
10% owner
2016 – 2020 · Public company (AVEO)
Trevi Therapeutics, Inc.
10% owner
2019 – 2020 · Public company (TRVI)
Black Diamond Therapeutics, Inc.
10% owner
2020 · Public company (BDTX)
Ardelyx, Inc.
10% owner
2016 – 2019 · Public company (ARDX)
Mirum Pharmaceuticals, Inc.
10% owner
2019 · Public company (MIRM)
Nightstar Therapeutics plc
10% owner
2019 · Public company (NITE)
Tempest Therapeutics, Inc.
10% owner
2018 · Public company (TPST)
Cascadian Therapeutics, Inc.
10% owner
2017 – 2018 · Public company (CASC)
Oruka Therapeutics, Inc.
10% owner
2015 – 2018 · Public company (ORKA)
Achaogen, Inc.
10% owner
2016 · Public company (AKAO)

Key Colleagues at Startups

The people Joshua Makower works with at each company, as listed on that company's latest Form D.

X9, Inc. · Form D, Dec 5, 2025
BM
MK
SP
EB
Earl Bright
Chief Executive Officer and director
Moximed, Inc · Form D, Aug 20, 2024
DA
SM
DM
MM
AC
Anton Clifford
Executive officer
James Leech
James Leech
Executive officer
MW
CG
Intrinsic Therapeutics Inc. · Form D, Apr 7, 2021
RD
Ryan Drant
Director
JD
GL
BV
CH
Carey Hagan
President and Chief Executive Officer, director
KS
Kevin Sidow
Director
Willow Innovations, Inc. · Form D, Oct 1, 2020
AC
Andrew Chmyz
Chief Financial Officer
IR
Ivy Ross
Director
NR
SF
Stacy Feld
Director
RC
Robert Croce
Director
LC
Laura Chambers
Executive officer and director
MC

Sources

  1. SECX9, Inc. Form D, filed Dec 5, 2025
  2. SECMoximed, Inc Form D, filed Aug 20, 2024
  3. SECIntrinsic Therapeutics Inc. Form D, filed Apr 7, 2021
  4. SECWillow Innovations, Inc. Form D, filed Oct 1, 2020
  5. SECForms 3, 4 and 5 filed by Joshua Makower (SEC filer 1235952)